<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03305887</url>
  </required_header>
  <id_info>
    <org_study_id>ESC-16-001</org_study_id>
    <nct_id>NCT03305887</nct_id>
  </id_info>
  <brief_title>Symmetric on Total Knee Arthoplasty (TKA)</brief_title>
  <acronym>SFX</acronym>
  <official_title>A Prospective, Multicenter, Randomized Controlled Study to Evaluate the Wound Closure Efficiency of STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device Compared to Conventional Sutures in Total Knee Arthoplasty (TKA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Medical, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Medical, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A post-marketing prospective, multicenter, randomized controlled study to evaluate the wound
      closure efficiency of STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device
      (STRATAFIX Symmetric PDS Plus) compared to conventional sutures in total knee arthoplasty
      (TKA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this prospective, randomized controlled study is to evaluate the
      wound closure efficiency of STRATAFIX Symmetric PDS Plus compared to conventional sutures in
      patients undergoing TKA. For the purpose of this study, wound closure efficiency is defined
      as the total time required to close the surgical incisions in patients undergoing TKA
      procedures using STRATAFIX Symmetric PDS Plus compared to those using traditional sutures.
      Secondary objectives will include the evaluation of differences in overall surgical procedure
      time, operating room (OR) time, length of stay, procedure costs, quality of life measures
      including pain, and range of motion (ROM). In addition, the difference in the safety profiles
      for both wound closure procedures will be evaluated through the analysis of the incidence of
      wound complications including dehiscence, wound infections, and other adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suturing time</measure>
    <time_frame>During Surgery</time_frame>
    <description>The total time required to close the surgical incisions between treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of procedure</measure>
    <time_frame>Instantly after Surgery</time_frame>
    <description>The total time required to conduct surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall OR time</measure>
    <time_frame>Instantly after Surgery</time_frame>
    <description>The total time required patient in operation room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days of surgery to discharge</measure>
    <time_frame>Through discharge, an average of 14days</time_frame>
    <description>Length of stay between surgery and discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TKA related QoL assessments1</measure>
    <time_frame>Screening; 3-5 days after surgery; 30-42 days after surgery</time_frame>
    <description>Knee pain measured by Visual Analogue Scale(VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TKA related QoL assessments 2</measure>
    <time_frame>Screening; 3-5 days after surgery; 30-42 days after surgery</time_frame>
    <description>Health-related quality of life measured by EQ-5D-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Site Infection (SSI)</measure>
    <time_frame>3-5 days after surgery; 30-42 days after surgery</time_frame>
    <description>As defined by CDC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asepsis score</measure>
    <time_frame>3-5 days after surgery; 30-42 days after surgery</time_frame>
    <description>Only for subjects with confirmed Surgical Site Infection(SSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Inflammatory Response Evaluation (AIRE) score</measure>
    <time_frame>3-5 days after surgery; 30-42 days after surgery</time_frame>
    <description>measuring inflammatory tissue reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wound separation or dehiscence Incidence</measure>
    <time_frame>3-5 days after surgery; 30-42 days after surgery</time_frame>
    <description>Incidence of wound separation or dehiscence requiring intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wound healing events Incidence</measure>
    <time_frame>3-5 days after surgery; 30-42 days after surgery</time_frame>
    <description>Incidence of delayed wound healing events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(serious) adverse events associated with wound closure Incidence</measure>
    <time_frame>Surgery; 3-5 days after surgery; 30-42 days after surgery</time_frame>
    <description>Incidence of adverse events (AEs) and serious adverse events (SAEs) associated with wound closure;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Wound Closure</condition>
  <arm_group>
    <arm_group_label>Barbed suture group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue suture respectively. STRATAFIX Spiral PGA-PCL sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional suture group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CR8 VICRYL® PLUS sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral PGA-PCL sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue</intervention_name>
    <description>This devices will be used in deep and intermediate layers of barbed suture group.</description>
    <arm_group_label>Barbed suture group</arm_group_label>
    <other_name>STRATAFIX Symmetric PDS Plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CR8 VICRYL® PLUS</intervention_name>
    <description>This devices will be used in deep and intermediate layers of conventional suture group.</description>
    <arm_group_label>Conventional suture group</arm_group_label>
    <other_name>CR8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STRATAFIX Spiral PGA-PCL sutures</intervention_name>
    <description>This devices will be used in intradermal layer of both barbed suture and conventional suture group.</description>
    <arm_group_label>Barbed suture group</arm_group_label>
    <arm_group_label>Conventional suture group</arm_group_label>
    <other_name>Spiral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DERMABOND™ Advance™ Skin Closure System</intervention_name>
    <description>This devices will be used in skin layer of both barbed suture and conventional suture group.</description>
    <arm_group_label>Barbed suture group</arm_group_label>
    <arm_group_label>Conventional suture group</arm_group_label>
    <other_name>DERMABOND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is ≥ 18 years and &lt; 80 years of age;

          2. Patient with osteoarthritis is scheduled to undergo elective unilateral TKA;

          3. Patient is willing to participate in the study, comply with study requirements,
             follow-up schedule, and give written informed consent; and

          4. Patient agrees not to schedule any additional elective surgical procedures until
             participation in this study is complete.

        Exclusion Criteria:

          1. Female patient who is pregnant or lactating at the time of screening;

          2. Patient has a Body Mass Index (BMI) &gt; 40 kg/m2;

          3. Patient is not able to walk independently (inability to walk at least 10 consecutive
             meters without a walking aid);

          4. Patient has had a surgical intervention during the past 30 days for treatment of
             painful joint or its underlying etiology;

          5. Patient has had previous open surgeries on the affected joint other than arthroscopy;

          6. Patient has active infectious collagen diseases (i.e. scleroderma) or any other
             condition that would interfere with wound healing;

          7. Patient is allergic to poly (p-dioxanon), IRGACARE®* MP (triclosan) or D&amp;C Violet No.
             2;

          8. Patient has diabetes with poor control, defined as fasting plasma glucose (FPG) ≥ 10.0
             mmol/L;

          9. Patient has a history of immunosuppressive drug use, including steroids, within the
             last 6 months;

         10. Patient has undergone chemotherapy or radiation within the last 6 months prior to
             study enrollment or is scheduled to do so during the study period;

         11. Patient has known personal or family history of keloid formation or hypertrophy;

         12. Patient has other dermatologic conditions known to impair wound healing;

         13. Patient is participating in any other investigational drug (within 30 days or 5
             half-lives of an investigational drug) or device study;

         14. Patient has any physical or psychological condition which would impair study
             participation; and

         15. Patient is judged unsuitable for study participation by the investigator for any other
             reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patty Schleckser</last_name>
    <role>Study Director</role>
    <affiliation>Ethicon, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Zhu</last_name>
    <phone>+86(0)21 33378215</phone>
    <email>qzhu15@ITS.JNJ.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tengfei Yang</last_name>
    <phone>+86(0)21 33378741</phone>
    <email>tyang11@its.jnj.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiying Chen</last_name>
      <phone>86 13901078832</phone>
      <email>chenjiying_301@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Chai</last_name>
      <phone>86 13601372998</phone>
      <email>chaiwei301@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jiying Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen Chai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NanFang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhanjun Shi</last_name>
      <phone>86 13503037919</phone>
      <email>nfgk@sohu.com</email>
    </contact>
    <contact_backup>
      <last_name>jian wang</last_name>
      <phone>86 13392127531</phone>
      <email>13392127531@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhanjun Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital affiliated Tongji medical college huazhonguniversity of science&amp;technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Xiao</last_name>
      <phone>86 13397115366</phone>
    </contact>
    <contact_backup>
      <last_name>Weikai Zhang</last_name>
      <phone>86 13407182012</phone>
      <email>wk-zhang@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Xiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weikai Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu province hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Liu</last_name>
      <phone>86 13915981848</phone>
      <email>njliuf@163.com</email>
    </contact>
    <investigator>
      <last_name>Feng Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin University Chinese Japanese Friendship Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianlin Zuo</last_name>
      <phone>86 13514483288</phone>
      <email>jlzuojianlin@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianlin Zuo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>second affiliated hospital of Xi'an Jiaotong university</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunzheng Wang</last_name>
      <phone>86 13809195901</phone>
      <email>wangkunzheng@21cn.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Wang</last_name>
      <phone>86 13384906990</phone>
      <email>dr.wangwei@xjtu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Kunzheng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shigui Yan</last_name>
      <phone>86 13906531308</phone>
      <email>zrjwsj@zju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Haobo wu</last_name>
      <phone>86 13958122387</phone>
      <email>haobo_wu@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shigui Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haobo Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TKA</keyword>
  <keyword>Barbed suture</keyword>
  <keyword>Surgical time</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

